Oculis treats first patient in PIONEER-1 registrational trial of Privosegtor for optic neuritis
Reuters2026/08/24 08:00- Oculis began dosing patients in PIONEER-1, a registrational trial of Privosegtor for acute-onset optic neuritis.
- No new efficacy results were presented; the trial’s primary analysis is planned at Month 3, with follow-up through Month 12.
- Privosegtor is positioned as a potential neuroprotective treatment designed to improve vision recovery in optic neuritis.
- The program builds on earlier Phase 2 findings that supported FDA Breakthrough Therapy designation, with an acute MS relapse IND targeted for Q4 2026.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Lazard paper warns global supply chains face O-ring-style single-point failures amid geopolitics
Andalan Perkasa Abadi says unaware of material information behind NASA share volatility
Massive Buyback Faces "Cold Reception"! U.S. Treasury Bond Purchase Plan Hits a Wall, Liquidity Tool Risks Becoming Ineffective
The US Treasury's expanded repo operations faced a record-low subscription ratio, highlighting a bottleneck in long-term bond market absorption, which may force officials to further cut issuance of the less liquid 20-year US Treasury bonds.
Crypto prices
More
